Navigation Links
Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
Date:1/27/2008

erapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin has been evaluated in more than 750 patients and has demonstrated activity in multiple indications with no evidence of significant kidney, nerve toxicity or hearing loss, toxicities commonly observed with other platinum chemotherapy drugs.

In addition to the Phase 2 clinical trial in patients with mCRC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint. The Company also is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial for the treatment of hormone refractory prostate cancer (HRPC). Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone- refractory prostate cancer, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by regulatory authority for use in humans. Fo
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
5. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
9. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  BC Technical, the nation,s ... Polaris Medical Imaging, a leader in sales, service and ... acquisition allows BC Technical to continue to expand their ... MR and CT modalities. "We are ... Mark Alvarez , president and CEO of BC ...
(Date:8/29/2014)... DENVER , Aug. 29, 2014 Does your ... date, nearly 800 doctors have recommended marijuana to the over ... Amendment 20. But the majority of the other roughly 20,300+ ... still know very little about it – even though a ... adults say they have tried it. ...
(Date:8/29/2014)... Diseases largely eradicated in the ... Measles was declared eliminated in 2000, yet the CDC ... 15—the highest incidence in 20 years. In July, ... cough a problem of "epidemic proportions." ... from these preventable diseases—in part because some parents (more ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... WESTON, Fla. , June 15 DHL Global Mail ... of mail-order pharmacies. DHL SMARTMAIL PHARMA SELECT ™ incorporates best ... the pharmaceutical industry. Thanks to this expertise and Global Mail,s nationwide ... accountability and value. , , ...
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President ... Goldman Sachs Global Healthcare Conference on Tuesday, June 15 , at ... in Los Angeles .  The presentation will be webcast on the ... , , ...
Cached Medicine Technology:DHL Global Mail Launches Specialized Shipping Service for Mail-Order Pharmacies 2
(Date:8/31/2014)... August 31, 2014 This September, ... California State Library, celebrates 30 years of changing ... Since its inception, California’s Library Literacy Services has ... learn to read and write. , To mark ... the state is launching a month-long awareness campaign ...
(Date:8/31/2014)... Sunday 31 August 2014: Renal denervation seems to ... with resistant hypertension when it includes accessory renal arteries, ... Dr Linda Schmiedel from Germany. , Dr Schmiedel said: ... hypertension, which is defined as blood pressure (BP) greater ... from resistant hypertension (rHTN) and are unable to reduce ...
(Date:8/30/2014)... August 2014: A new method to predict the ... was presented at ESC Congress today by Dr Benjamin ... needs 350 AEDs located in public places for optimal ... Dr Dahan said: "Out of hospital cardiac arrest is ... ranging between 50 and 100 per 100 000 in ...
(Date:8/30/2014)... Walking-Canes.Net has released several articles related ... can help in making gait problems easier. The new ... website that contains all of the news articles that were ... articles deal with diseases that make walking a problem and ... help in making life easier for the patient. The articles ...
(Date:8/30/2014)... Cokato, MN (PRWEB) August 31, 2014 ... renewed in home renovation, especially spa style bathrooms and ... (NASS) has observed an increase in interest not ... understanding the history, culture and health benefits of sauna. ... Finnleo , the North American Sauna Society provides ...
Breaking Medicine News(10 mins):Health News:California Library Literacy Services Celebrates 30th Anniversary 2Health News:California Library Literacy Services Celebrates 30th Anniversary 3Health News:Renal denervation more successful when it includes accessory arteries 2Health News:New method predicts optimal number and location of AEDs 2Health News:Information Articles on Gait Problems from Walking-Canes.Net 2Health News:As Interest in Saunas Increases, the North American Sauna Society Increases Outreach to Provide Education on History, Design, and Culture 2
... compared to kids without disorder , MONDAY, Oct. 19 ... in blood mercury levels between children who are developing ... disorders. , The findings, appearing online Oct. 19 in ... some of the debate surrounding mercury and autism. , ...
... not trained in skin cancer examinations, nor have they ever ... the October issue of Archives of Dermatology , one ... that can be detected early for which U.S. death rates ... Although melanoma remains the second most common cause of cancer ...
... WASHINGTON, D.C., October 19, 2009 With chronic diseases ... solutions to improve care and outcomes for these often ... today announced a new initiative funded with a grant ... will allow pediatricians across the country to pilot a ...
... a joint letter to the Centers for Medicare and ... fluorodeoxyglucose (FDG) positron emission tomography (PET) scans for a ... only one FDG-PET study during initial treatmenta limitation that ... under certain circumstances. "It is absolutely critical for ...
... ... Assara Laser Cosmetic Services Centers and Park Avenue Laser Vision ... dedication to providing exemplary care in the cutting-edge laser cosmetics field. ... laser spider vein removal and laser facials. Park Avenue Laser Vision ...
... ... Access, Choice, and Flexibility. , ... Albany, NY (Vocus) October 19, 2009 -- In a continuous effort to develop products and ... benefits, CDPHP ® announces several enhancements to take effect in 2010 pending New York ...
Cached Medicine News:Health News:Mercury Levels Not Abnormal in Autistic Children 2Health News:Mercury Levels Not Abnormal in Autistic Children 3Health News:Resident physicians seldom trained in skin cancer examination 2Health News:Pediatricians put proven treatment strategies to work against childhood asthma 2Health News:1 scan per patient is not always enough 2Health News:Assara Laser Announces Strategic Alliance with Park Avenue Laser Vision 2Health News:Assara Laser Announces Strategic Alliance with Park Avenue Laser Vision 3Health News:CDPHP Launches National Network and Three-In-One Plan, and Expands Member Incentives 2Health News:CDPHP Launches National Network and Three-In-One Plan, and Expands Member Incentives 3Health News:CDPHP Launches National Network and Three-In-One Plan, and Expands Member Incentives 4
Comfor™ Cast Boot - Rocker Sole - Closed Toe...
The Multi-Purpose Medical-Surgical Shoe...
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... For use as a non-reactive quality assurance reagent ... Toxoplasma gondii (TOXO IgG and TOXO IgM), IgG ... and rubella IgM), IgG and IgM antibodies to ... IgM antibodies to herpes simplex virus types 1 ...
Medicine Products: